6/20/2018 | BKCV | S&P changes Albany Molecular view
|
7/27/2017 | BKCV | S&P lowers Albany Molecular’s first-lien loans
|
7/19/2017 | BKCV | Moody’s: UIC Merger/Albany Molecular facilities B2, Caa2
|
7/19/2017 | BKCV | S&P: Albany Molecular loans B+, B-
|
6/7/2017 | BKCV | S&P might lower Albany Molecular
|
2/21/2017 | CV | Market Commentary: Holiday weighs on convertible bond volume; primary calendar builds; Vipshop firms
|
5/11/2016 | BKCVDD | S&P lowers Albany Molecular loans to B
|
7/27/2015 | BKCV | Moody’s rates Albany Molecular CFR B3, loans B1
|
7/24/2015 | BKCVDD | S&P rates Albany Molecular loans B+, convertibles CCC+
|
1/21/2014 | CV | Market Commentary: NQ Mobile, Teva Pharmaceutical better on swap; Yandex in trade; YRC Worldwide in focus
|
12/4/2013 | CV | Albany Molecular greenshoe lifts 2.25% convertibles to $150 million
|
11/20/2013 | CV | New Issue: Albany Molecular sells upsized $130 million five-year convertibles at 2.25%, up 32%
|
11/20/2013 | CV | Market Commentary: Blackstone adds on hedge; new Cardtronics, Albany Molecular slip; Yahoo! upsizes; WebMD on tap
|
11/20/2013 | CV | Market Commentary: Midday Commentary: New Cardtronics, Albany Molecular hover near par; Yahoo! offering in focus
|
11/19/2013 | CV | Albany Molecular plans $100 million five-year convertibles to yield 2%-2.5%, up 27.5%-32.5%
|
11/19/2013 | CV | Market Commentary: New Energy XXI trades around par; new Horizon Pharma surges with shares; Yahoo! to price
|
12/22/2011 | CVPF | Albany Molecular Research files $50 million stock, preferreds shelf
|